About Us

Glioblastoma (GBM) is the most common and malignant of all primary brain cancers. All GBM patients undergo the same non-curative treatment, including surgery, chemotherapy and radiation therapy. This regimen invariably fails because GBM cells infiltrate the tissue surrounding the tumor where they are protected from chemotherapy by the blood brain barrier (BBB). 

The Sonabend Lab conducts translational research that aims to improve the survival outcomes of patients living with GBM. Sonabend's main research interests are in understanding the physiology of the BBB and facilitating the delivery of chemotherapy to the brain. The lab is conducting a clinical trial that uses an implantable ultrasound device to focally disrupt the BBB surrounding the tumor and enhance the delivery of paclitaxel to treat GBM. The lab also focuses on identifying tumoral biomarkers from patients on our trial, which could indicate susceptibility to specific chemotherapy regimens. 

The lab welcomes your questions and comments. For general feedback and inquries, please contact us for more information via our office information below or meet our team to reach out to individuals. See our Careers page for information on joining the team.